Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Progranulin (PGRN), a widely expressed glycoprotein with pleiotropic function, has been linked to a host of physiological processes and diverse pathological states. Currently, various therapeutic strategies targeting PGRN have been developed in a series of preclinical models of diseases and clinical trials, highlighting PGRN as a promising target in diseases treatment. Herein we summarize available knowledge of PGRN targeting in various kinds of diseases, including common neurological diseases, inflammatory autoimmune diseases, cancer, tissue repair, and rare lysosomal storage diseases, with the focus on the functional domain-oriented drug development strategies. In particular, we emphasize the potential role of PGRN as a non-conventional, extracellular matrix bound, growth factor-like conductor orchestrating multiple membrane receptors and simultaneously as an intracellular co-chaperone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Tang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761
Self-citationProgranulin is a mediator of the wound response
He, Z., Ong, C. H. P., Halper, J., & Bateman, A. (2003) · Nature Medicine · doi:10.1038/nm816 · Cited by 490
Strikingly Different Clinicopathological Phenotypes Determined by Progranulin-Mutation Dosage
Smith, K. R., Damiano, J., Franceschetti, S., Carpenter, S., Canafoglia, L., Morbin, M., Rossi, G., Pareyson, D., Mole, S. E., Staropoli, J. F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.04.021 · Cited by 489
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., Ma, X., Ma, Y., Iadecola, C., Beal, M. F., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091568 · Cited by 480
Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models
Minami, S. S., Min, S.-W., Krabbe, G., Wang, C., Zhou, Y., Asgarov, R., Li, Y., Martens, L. H., Elia, L. P., Ward, M. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3672 · Cited by 237
The lysosomal function of progranulin, a guardian against neurodegeneration
Paushter, D. H., Du, H., Feng, T., & Hu, F. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1861-8 · Cited by 230
Elkabets, M., Gifford, A. M., Scheel, C., Nilsson, B., Reinhardt, F., Bray, M.-A., Carpenter, A. E., Jirström, K., Magnusson, K., Ebert, B. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43757 · Cited by 201
Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis
Ward, M. E., Chen, R., Huang, H.-Y., Ludwig, C., Telpoukhovskaia, M., Taubes, A., Boudin, H., Minami, S. S., Reichert, M., Albrecht, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5642 · Cited by 193
Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
Progranulin Gene Delivery Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease
Van Kampen, J. M., Baranowski, D., & Kay, D. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097032 · Cited by 76
Sha, S. J., Miller, Z. A., Min, S., Zhou, Y., Brown, J., Mitic, L. L., Karydas, A., Koestler, M., Tsai, R., Corbetta‐Rastelli, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.002 · Cited by 36
Cited by
Progranulin as a therapeutic target in neurodegenerative diseases
Rhinn, H., Tatton, N., McCaughey, S., Kurnellas, M., & Rosenthal, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.015 · Cited by 208
Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses
Butz, E. S., Chandrachud, U., Mole, S. E., & Cotman, S. L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165571 · Cited by 62
Asken, B. M., Ljubenkov, P. A., Staffaroni, A. M., Casaletto, K. B., Vandevrede, L., Cobigo, Y., Rojas-Rodriguez, J. C., Rankin, K. P., Kornak, J., Heuer, H., et al. (2023) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330866 · Cited by 16
“36 37 In GRN , peripheral markers of key regulators within monocyte activation pathways were shown previously to be elevated cross-sectionally compared with controls and associated with worse white matter integrity.”
Background
Metadata
- Authors
- Cui, Y., Hettinghouse, A., & Liu, C.-J.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 45
- Pages
- 53-64
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W2911512153
- Cited by
- 80
- References
- 13
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.